BREAKING NEWS: Rising
Biosciences Expedites Growth/Expansion with
In-House Chemist, Laboratory Analytical Equipment and
Producer/Processor Contracts
Sandusky, OH
-- March 20, 2018 -- InvestorsHub
NewsWire -- Rising India, Inc.'s (OTC:RSII)
-- Rising Biosciences, Inc., a
research and development company focusing on oral and topical
pharmaceuticals with strict standards set forward by the
pharmaceutical compounding industry, is pleased to announce
that it has
launched near-term initiatives to expedite growth for long-term
shareholder value.
We are
thrilled to announce that Rising Biosciences will also be rolling
out its RBS0238 CLINICAL PEPTIDE SERUM
(our scar
serum) in Q2. "We could not be
more excited to announce that after a recent meeting with
the
manufacturer of
our clinical strength peptide
serum, we are officially
entering
production phase for the product line
and it will on sale, available
for national
distribution, in late April/early May,"
states Hall. "This means revenues, revenues and more
revenues."
"As well,
we have
corresponded in regards to the FDA testing procedures on our TSW
pain cream and they continue to progress
to what we feel will be near-term completion."
The Company
has also recently hired a seasoned
chemist who will serve as Chief Chemist in-house at the Company's
Ohio Laboratory. COO Arthur Hall
states, "Our Chief Chemist will be
traveling to Florida to train with our staff
there on
overall procedures and protocol. We are thrilled to have secured
talent at this level which will greatly expedite research and
development on new product ideas as well as staff expertise in all
of our locations."
"As well, we
have purchased analytical equipment which will allow us to do
developmental testing on-site as opposed to the costly and timely
procedure of shipping to an outside laboratory. The equipment is
paid for and scheduled to be installed next week."
The Company
also announces updates on expansion and have entered into contracting
stages with two California Producer/Processors, one of which also
has operations and facilities in Arizona for manufacturing
Cannophen
and TSW pain
cream with CBD/THC. A Producer/Processor grows or extracts (THC,
CBD, etc.) directly from flower and also processes and manufactures
MMJ products. "We anticipate this to effect a near-term multiplier
regarding overall operations and potential
revenues."
"The Medical
Marijuana revolution has only begun," states Hall.
"The US government recently
updated content pages on the National Cancer Institute's (an
official division of the US Department of Health)
website to include information
about, cannabis and cannabinoids."
The new
updates, implemented in January, include information indicating
that cannabis and cannabinoids can kill cancer
without damaging the body's normal
cells.
The National
Cancer Institute states a number of facts about Antitumor activity
and pain relief, among others, citing studies
in mice and rats which
have shown
that cannabinoids may inhibit tumor growth by causing cell death,
blocking cell growth, and blocking the development of blood vessels
needed by tumors to grow. Laboratory and animal
studies have
shown that cannabinoids may be able to kill cancer cells while
protecting normal cells. As well, it
goes on to state that A
laboratory
study of cannabidiol
(CBD) in
human glioma
cells showed
that when given along with chemotherapy,
CBD may make chemotherapy more effective and increase cancer cell
death without harming normal cells. Studies in mouse models of
cancer showed that CBD together with delta-9-THC
may
make
chemotherapy such as temozolomide more
effective.
"We are on
the cusp of something fantastic here and are grateful for continued
shareholder participation. We are developing life-changing products
and anticipate continued shareholder value alongside assertive
R&D initiatives, partnerships and acquisitions as well as both
B2B and B2C sales strategies for our product lines," concludes
Hall.
Hall is
planning trips to Colorado and Michigan in the coming weeks
to meet with
producers and processors in those markets, among others on the
company's agenda.
"Rising Biosciences Inc. along with PAO Group Inc.
helping reduce the grip of opiods on America through the
responsible use of cannabis"
$RSII on
Twitter for LIVE company updates! www.twitter.com/risingindiausa
Forward-Looking Statements:
Certain statements in this news release may contain forward-looking
information within the meaning of Rule 175 under the Securities Act
of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934,
and are subject to the safe harbor created by those rules. All
statements, other than statements of fact, included in this
release, including, without limitation, statements regarding
potential future plans and objectives of the company, are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those anticipated in such statements. Technical
complications, which may arise, could prevent the prompt
implementation of any strategically significant plan(s) outlined
above. The Company undertakes no duty to revise or update any
forward- looking statements to reflect events or circumstances
after the date of this release.
CONTACT
INFO:
For Investor
Inquiries:
IR@risingbiosciences.com
